株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

脳炎:パイプライン製品の分析

Encephalitis - Pipeline Review, H1 2019

発行 Global Markets Direct 商品コード 465220
出版日 ページ情報 英文 37 Pages
即納可能
価格
本日の銀行送金レート: 1USD=108.97円で換算しております。
Back to Top
脳炎:パイプライン製品の分析 Encephalitis - Pipeline Review, H1 2019
出版日: 2019年01月31日 ページ情報: 英文 37 Pages
概要

脳炎とは脳組織の炎症であり、大きく分けて一次性と二次性の2種類があります。一次性脳炎は、ウィルスが直接脳および脊髄に感染して発症します。二次性脳炎は、体のどこか他の場所で感染し、それが脳に移動して発症します。原因には、一般的なウィルス、小児が感染するウィルス、アルボウィルスがあります。危険因子として、年齢、免疫力の低下が挙げられます。症状は、熱、頭痛、嘔吐、斜頸、昏睡および幻覚などがあります。治療には、鎮痛剤、副腎皮質ステロイド、鎮痙剤、鎮静剤などを用います。

当レポートでは、脳炎の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

脳炎;概要

治療薬の開発

  • パイプライン製品;概要
  • 企業別の製品
  • 大学/研究機関別のパイプライン製品
  • 企業で開発中の製品
  • 大学/研究機関で開発中の製品

治療薬の評価

  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

治療薬開発に従事している企業

  • Aeterna Zentaris Inc
  • CEL-SCI Corp
  • Prosetta Biosciences Inc
  • Sage Therapeutics Inc

薬剤プロファイル

  • アンフォテリシン B ナトリウム
  • CEL-1000
  • ミルテホシン
  • PAV-645
  • 肺炎球菌 (23価) ワクチン
  • 急性脳炎向けポリグラクチン370
  • SAGE-718
  • ウィルス感染症向け小分子
  • VY-OZ

休止中のプロジェクト

製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

図表

図表

List of Tables

  • Number of Products under Development for Encephalitis, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Products under Development by Companies, H1 2019
  • Number of Products by Stage and Target, H1 2019
  • Number of Products by Stage and Mechanism of Action, H1 2019
  • Number of Products by Stage and Route of Administration, H1 2019
  • Number of Products by Stage and Molecule Type, H1 2019
  • Encephalitis - Pipeline by CEL-SCI Corp, H1 2019
  • Encephalitis - Pipeline by Knight Therapeutics Inc, H1 2019
  • Encephalitis - Pipeline by Sage Therapeutics Inc, H1 2019
  • Encephalitis - Dormant Projects, H1 2019

List of Figures

  • Number of Products under Development for Encephalitis, H1 2019
  • Number of Products under Development by Companies, H1 2019
  • Number of Products by Targets, H1 2019
  • Number of Products by Stage and Targets, H1 2019
  • Number of Products by Mechanism of Actions, H1 2019
  • Number of Products by Stage and Mechanism of Actions, H1 2019
  • Number of Products by Routes of Administration, H1 2019
  • Number of Products by Stage and Routes of Administration, H1 2019
  • Number of Products by Molecule Types, H1 2019
  • Number of Products by Stage and Molecule Types, H1 2019
目次
Product Code: GMDHC11050IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Encephalitis - Pipeline Review, H1 2019, provides an overview of the Encephalitis (Central Nervous System) pipeline landscape.

Encephalitis is an inflammation of the brain tissue. There are two main types of encephalitis: primary and secondary. Primary encephalitis occurs when a virus directly infects the brain and spinal cord. Secondary encephalitis occurs when an infection starts elsewhere in the body and then travels to brain. Causes include common viruses, childhood viruses, and arboviruses. Risk factors include age and weak immune systems. Symptoms include fever, headache, vomiting, stiff neck, coma and hallucinations. Treatment includes pain killers, corticosteroids, anticonvulsants and sedatives.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Encephalitis - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Encephalitis (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Encephalitis (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Encephalitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I and Preclinical stages are 1 and 6 respectively.

Encephalitis (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Encephalitis (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Encephalitis (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Encephalitis (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Encephalitis (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Encephalitis (Central Nervous System)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Encephalitis (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Encephalitis (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Encephalitis - Overview
  • Encephalitis - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Encephalitis - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Encephalitis - Companies Involved in Therapeutics Development
    • CEL-SCI Corp
    • Knight Therapeutics Inc
    • Sage Therapeutics Inc
  • Encephalitis - Drug Profiles
    • Amphotericin B sodium - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CEL-1000 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • miltefosine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pneumococcal (13-valent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pneumococcal (23-valent) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Polyglactin 370 for Encephalitis - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAGE-718 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Encephalitis - Dormant Projects
  • Encephalitis - Product Development Milestones
    • Featured News & Press Releases
      • Jul 06, 2018: Knight receives adverse notice of reassessment from CRA
      • Jun 28, 2017: FDA Grants Profounda Orphan Drug Designation for treatment of Granulomatous Amebic Encephalitis (GAE) with Miltefosine
      • Dec 17, 2016: Profounda receives FDA orphan-drug designation for the Treatment of Primary Amebic Meningoencephalitis (PAM) with Miltefosine
      • Aug 24, 2016: Orlando patient survives Primary Amebic Meningoencephalitis using Profoundas drug Impavido (miltefosine)
      • Dec 15, 2015: U.S. Issues Patent on Corifungin
      • Feb 26, 2013: National Institutes of Health Supports Acea's Research
      • Aug 22, 2011: Dr. James McKerrow, efficacy of Corifungin vs. Naegleria
      • Aug 22, 2011: FDA Grants 2nd Orphan drug designation
      • Feb 10, 2010: Dr. Jose Vazquez presents poster at ICAAC
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer
Back to Top